Cutaneous lupus erythematosus: Diagnosis and management

American Journal of Clinical Dermatology

Volumn 4, Issue 7, 2003, Pages 449-465

  Fabbri, Paolo ^a   Cardinali, Carla ^a,b   Giomi, Barbara ^a   Caproni, Marzia ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACEBUTOLOL; ALLOPURINOL; ALPHA2B INTERFERON; AMINOGLUTETHIMIDE; AMINOQUINOLINE DERIVATIVE; ANTIMALARIAL AGENT; AURANOFIN; AUROTHIOGLUCOSE; AUROTHIOMALATE; AZATHIOPRINE; CHLOROQUINE; CLOFAZIMINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DAPSONE; ETRETINATE; HYDROCHLOROTHIAZIDE; HYDROXYCHLOROQUINE; ISOTRETINOIN; MEPACRINE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RETINOID; TAZAROTENE; TERBINAFINE; THALIDOMIDE; UNINDEXED DRUG;

AMENORRHEA; BLOOD TOXICITY; CLINICAL PRACTICE; CONSTIPATION; DISCOID LUPUS ERYTHEMATOSUS; DISEASE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG CHOICE; FATIGUE; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; HUMAN; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LIVER TOXICITY; LUPUS ERYTHEMATOSUS; PHOTOSENSITIVITY; POLYNEUROPATHY; PRIORITY JOURNAL; RETINA DISEASE; REVIEW; SKIN LUPUS ERYTHEMATOSUS; SUNLIGHT PROTECTION; TERATOGENESIS; TERATOGENICITY; TISSUE SPECIFICITY; VASCULITIS; VERTIGO; WEIGHT GAIN; XEROSTOMIA;

ACUTE DISEASE; CHRONIC DISEASE; HUMANS; LUPUS ERYTHEMATOSUS, CUTANEOUS; LUPUS ERYTHEMATOSUS, DISCOID;

EID: 0037766691     PISSN: 11750561     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128071-200304070-00002     Document Type: Review

References (113)

1. Gilliam JN, Sontheimer RD. Distinctive cutaneous subsets in the spectrum of lupus erythematosus. J Am Acad Dermatol 1981; 4: 471-5
2. Cardinali C, Caproni M, Bernacchi E, et al. The spectrum of cutaneous manifestations in lupus erythematosus-the Italian experience. Lupus 2000; 9: 417-23
3. Rothfield NF. Chronic discoid lupus erythematosus. In: Fitzpatrick TB, Eisen AZ, Wolff K, Austen KF, editors. Dermatology in general medicine. New York: McGraw-Hill, 1993: 2137
4. Callen JP. Chronic cutaneous lupus erythematosus. Arch Derm 1982; 118: 412-6
5. Millard LG, Rowell NR, Abnormal laboratory test results and their relationship to prognosis in discoid lupus erythematosus. Arch Dermatol 1979; 115: 1055-8
6. Rook A, Wilkinson DS, Ebling FJC. Textbook of dermatology. Oxford: Blackwell, 1992: 2171-4
7. Callen JP, Tuffanelli DL, Provost TT. Collagen-vascular disease: an update. J Am Acad Dermatol 1993; 28: 477-84
8. Su WP, Perniciaro C, Rogers RS, et al. Chilblain lupus erythematosus (lupus pernio): clinical review of the Mayo Clinic experience and proposal of diagnostic criteria. Cutis 1994; 54: 395-9
9. Sontheimer RD. The lexicon of cutaneous lupus erythematosus: a review and personal perspective on the nomenclature and classification of the cutaneous manifestations of lupus erythematosus. Lupus 1997; 6: 84-95
10. Sontheimer RD. Subacute cutaneous lupus erythematosus: a decade's perspective. Med Clin North Am 1989; 73: 1073-86
11. Gammon WR, Briggaman RA. Bullous SLE: a phenotypically distinctive but immunologically heterogeneous disorder. J Invest Dermatol 1993; 100: 28S-34S
12. Yell JA, Allen J, Wojnarowska F, et al. Bullous systemic lupus erythematosus: revised criteria for diagnosis. Br J Dermatol 1995; 132: 921-8
13. Drake LA, Dinehart SM, Farmer ER, et al. Guidelines of care for cutaneous lupus erythematosus. J Am Acad Dermatol 1996; 34: 830-6
14. Millard TP, Hawk JLM, McGregor JM. Photosensitivity in lupus. Lupus 2000; 9: 3-10
15. Cardinali C, Caproni M, Fabbri P. The utility of the lupus band test on sun-protected non-lesional skin for the diagnosis of systemic lupus erythematosus. Clin Exp Rheumatol 1999; 17: 427-32
16. Cardinali C, Caproni M, Fabbri P. The composition of the lupus band test (LBT) on the sun-protected non-lesional (SPNL) skin in patients with cutaneous lupus erythematosus (CLE). Lupus 1999; 8: 755-60
17. Callen JP, Fowler JF, Kulick KB. Serologic and clinical features of patients with discoid lupus erythematosus: relationship of antibodies to single-stranded deoxyribonucleic acid and of other antinuclear antibody subsets to clinical manifestations. J Am Acad Dermatol 1985; 13: 748-55
18. Shrank AB, Doniach D. Discoid lupus erythematosus. Arch Dermatol 1963; 87: 677-85
19. Kimberly RE, Burke WA. Treatment of localized discoid lupus erythematosus with tazarotene. J Am Acad Dermatol 1999; 41: 1049-50
20. Werth V. Current treatment of cutaneous lupus erythematosus. Dermatol Online J 2001; 7 (1): 2
21. Sontheimer RD. Questions answered and a $1 million question raised concerning lupus erythematosus tumidus: is routine laboratory surveillance testing during treatment with hydroxychloroquine for skin disease really necessary? Arch Dermatol 2000; 136: 1044-9
22. Karim MY, Ruiz-Irastorza G, Khamashta MA, et al. Update on the therapy-thalidomide in the treatment of lupus. Lupus 2001; 10: 188-92
23. Ordi-Ros J, Cortes F, Cucurull E, et al. Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy. J Rheumatol 2000; 27: 1429-33
24. Kyriakis KP, Kontochristopoulos GJ, Panteleos DN. Experience with low-dose thalidomide therapy in chronic discoid lupus erythematosus. Int J Dermatol 2000; 39: 218-22
25. Delaporte E, Catteau B, Sabbagh N, et al. Treatment of discoid lupus erythemamsus with sulfasalazine. Ann Dermatol Venereol 1997; 124: 151-6
26. Goyal S, Nousari HC. Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol 2001; 45: 142-4
27. Dalziel K, Going G, Cartwright PH, et al. Treatment of chronic discoid lupus erythematosus with an oral compound (auranofin). Br J Dermatol 1986; 115: 211-6
28. Kuhn A, Becker-Wegerich PM, Ruzika T, et al. Successful treatment of discoid lupus erythematosus with argon laser. Dermatology 2000; 201: 175-7
29. Mascaro JM, Herrero C, Hausmann G. Uncommon cutaneous manifestations of lupus erythematosus. Lupus 1997; 6: 122-31
30. Callen JP. Discoid lupus erythematosus: variants and clinical associations. In: Callen JP, editor. Clinics in Dermatology. Philadelphia: Lippincott JB, 1985: 49-57
31. Spann CR, Callen JP, Klein JB, et al. Clinical, serologic and immunogenetic studies in patients with chronic cutaneous (discoid) lupus erythematosus who have verrucous and/or hypertrophic skin lesions. J Rheumatol 1988; 15: 256-61
32. Uitto J, Santa-Cruz DJ, Eisen AZ, et al. Verrucous lesion in patients with discoid lupus erythematosus: clinical, histopathological and immunofluorescence studies. Br J Dermatol 1978; 98: 507-20
33. Santa-Cruz DJ, Uitto J, Eisen AZ, et al. Verrucous lupus erythematosus: ultrastructural studies on a distinct variant of chronic discoid lupus erythematosus. J Am Acad Dermatol 1983; 9: 82-90
34. Verbov J. The place of intralesional steroid therapy in dermatology. Br J Dermatol 1976; 94: 51-8
35. Seiger E, Roland S, Goldman S. Cutaneous lupus treated with topical tretinoin: a case report. Curtis 1991; 47: 351-5
36. Green S, Piette W. Treatment of hypertrophic lupus erythematosus with isotretinoin. J Am Acad Dermatol 1987; 17: 364-8
37. Izumi AK, Takiguchi P. Lupus erythematosus panniculitis. Arch Dermatol 1983; 119: 61-4
38. Sanchez NP, Peters MS, Winklemann RK. The histopathology of lupus erythematosus panniculitis. J Am Acad Dermatol 1981; 5: 673-80
39. Yamada Y, Dekio S, Jidoi J, et al. Lupus erythematosus profundus -report of a case treated with dapsone. J Dermatol 1989; 16: 379-82
40. Burrows NP, Walport MJ, Hammond AH, et al. Lupus erythematosus profundus with partial C4 deficiency responding to thalidomide. Br J Dermatol 1991; 125: 62-7
41. Millard LG, Rowell NR. Chilblain lupus erythematosus (Hutchinson): a clinical and laboratory study of 17 patients. Br J Dermatol 1978; 98: 497-506
42. Doutre MS, Beylot C, Beylot J, et al. Chilblain lupus erythematosus: report of 15 cases. Dermatology 1992; 184: 26-8
43. Aoki T, Ishizawa T, Hozumi Y, et al. Chilblain lupus erythematosus of Hutchinson responding to surgical treatment: a report of two patients with anti-Ro/SSA antibodies. Br J Dermatol 1996; 134: 533-7
44. Allegue F, Alonso ML, Rocamora A, et al. Chilblain lupus erythematosus and antiphospholipid antibody syndrome. J Am Acad Dermatol 1988; 19: 908-10
45. Rowell NR. Chilblain lupus erythematosus responding to etretinate. Br J Dermatol 1987; 117: 100-2
46. Boehm I, Bieber T. Chilblain lupus erythematosus Hutchinson: successful treatment with mycophenolate mofetil. Arch Dermatol 2001; 137: 235-6
47. Kuhn A, Sonntag M, Richter-Hintz D, et al. Phototesting in lupus erythematosus tumidus -review of 60 patients. Photochem Photobiol 2001; 73: 532-6
48. Goerz G, Lehmann P, Schuppe HC, et al. Lupus erythematosus. Z Hautkr 1990; 65: 229-34
49. Kind P, Goerz G. Der kutane lupus erythematodes (LE). In: Macher E, Knop J. Bröcker EB, editors. Jahrbuch der Dermatologie. Münster, Germany: Biermann Verlag, 1988: 85-103
50. Kind P, Schuppe HC, Goerz G. Kutaner Lupus erythematodes. Dtsch Ärztebl 1992; 49: 2121-30
51. Kuhn A, Richter-Hintz D, Oslislo C, et al. Lupus erythematosus tumidus: a neglected subset of cutaneous lupus erythematosus: report of 40 cases. Arch Dermatol 2000; 136: 1033-41
52. Sontheimer RD, Thomas JR, Gilliam JN. Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset. Arch Dermatol 1979; 115: 1409-15
53. Callen JP, Klein J. Subacute cutaneous lupus erythematosus: clinical, serologic, immunogenetic, and therapeutic considerations in seventy-two patients. Arthritis Rheum 1988; 31: 1007-13
54. Cohen MR, Crosby D. Systemic disease in subacute cutaneous lupus erythematosus: a controlled comparison with systemic lupus erythematosus. J Rheumatol 1994; 21: 1665-9
55. Fabbri P, Bernacchi E, Neri R. Subacute cutaneous lupus erythematosus: review of the literature and immunological studies of 11 patients. G Ital Dermatol Venereol 1990; 125: 329-36
56. David-Bajar KM. What's new in cutaneous lupus syndromes: subacute cutaneous lupus erythematosus. J Invest Dermatol 1993; 100: 2s-8s
57. Parodi A, Caproni M, Cardinali C, et al. Clinical, histological and immunopathological features of 58 patients with subacute cutaneous lupus erythematosus: a review by the Italian Group of Immunodermatology. Dermatology 2000; 200: 6-10
58. Reed BR, Huff JC, Jones SK, et al. Subacute cutaneous lupus erythematosus associated with hydrochlorothiazide therapy. Ann Intern Med 1985; 103: 49-51
59. Callen JP, Hughes AP, Kulp-Shorten C. Subacute cutaneous lupus erythematosus induced or exacerbated by terbinafine: a report of 5 cases. Arch Dermatol 2001; 137: 1196-8
60. Bonsmann G, Schiller M, Luger TA, et al. Terbinafine-induced subacute cutaneous lupus erythematosus. J Am Acad Dermatol 2001; 44: 925-31
61. Despain J, Clark DP. Subacute cutaneous lupus erythematosus presenting as erythroderma. J Am Acad Dermatol 1988; 19: 388-92
62. Bielsa I, Herrero C, Font J, et al. Lupus erythematosus and toxic epidermal necrolysis. J Am Acad Dermatol 1987; 16: 1265-7
63. Jenkins RE, Kurwa AR, Atherton DJ, et al. Neonatal lupus erythematosus. Clin Exp Dermatol 1994; 19: 409-11
64. Scheinman PL. Acral subacute cutaneous lupus erythematosus: an unusual variant. J Am Acad Dermatol 1994; 30: 800-1
65. Tsutsui K, Imai T, Hatta N, et al. Widespread pruritic plaques in a patient with subacute cutaneous lupus erythematosus and hypocomplementemia: response to dapsone therapy. J Am Acad Dermatol 1996; 35: 313-5
66. Pramatarov K, Vassileva S, Miteva L. Subacute cutaneous lupus erythematosus presenting with generalized poikiloderma. J Am Acad Dermatol 2000; 42: 286-8
67. Lever WF, Schaumburg-Lever G. Connective tissue diseases. In: Lever WF. Schaumburg-Lever G, editors. Histopathology of the skin. 7th ed. Philadelphia: JB Lippincott Company, 1989: 494-522
68. Nieboer C, Tak-Diamand Z, Vanleeuwen-Wallau HE. Dust-like particles: a specific direct immunofluorescence pattern in subacute cutaneous lupus erythematosus. Br J Dermatol 1988; 194: 217-20
69. Alspaugh MA, Talal N, Tan EM Differentiation and characterization of autoantibodies and their antigens in Sjögren's syndrome. Arthritis Rheum 1976; 19: 216-22
70. Scopelitis E, Biundo JJ, Alspaugh MA. Anti-SSA antibody and other antinuclear antibodies in systemic lupus erythematosus. Arthritis Rheum 1980; 23: 287-93
71. Jenkins RE, Kurwa AR, Atherton DJ, et al. Neonatal lupus erythematosus. Clin Exp Dermatol 1994; 19: 409-11
72. Reichlin M. Clinical and immunological significance of antibodies to Ro and La in systemic lupus erythematosus. Arthritis Rheum 1982; 25: 767-72
73. Jones SK. Ultraviolet radiation (UVR) induces cell-surface Ro/SSA antigen expression by human keratinocytes in vitro: a possible mechanism for the UVR cutaneous lesions. Br J Dermatol 1992; 126: 546-53
74. Versapuech J, Beylot-Barry M, Doutre MS, et al. Subacute cutaneous lupus: evolutive and therapeutic features of a series of 24 cases. Presse Med 2000; 29: 1596-9
75. Doutre MS, Beylot-Barry M, Beylot C. Subacute cutaneous lupus erythematosus. Presse Med 2000; 29: 1311-6
76. Furner BB. Subacute cutaneous lupus erythematosus response to isotretinoin. Int J Dermatol 1990; 29: 587-90
77. Kuhn A, Specker C, Ruzicka T, et al. Methotrexate treatment for refractory subacute cutaneous lupus erythematosus. J Am Acad Dermatol 2002; 46: 600-3
78. Bohm L, Uerlich M, Bauer R. Rapid improvement of subacute cutaneous lupus erythematosus with low-dose methotrexate. Dermatology 1997; 194: 307-8
79. Watanabe T, Tsuchida T. Classification of lupus erythematosus based upon cutaneous manifestations. Dermatology 1995; 190: 277-83
80. Wysenbeek AJ, Guedj D, Amit M, et al. Rash in systemic lupus erythematosus: prevalence and relation to cutaneous and non-cutaneous disease manifestations. Ann Rheum Dis 1992; 51: 717-9
81. Chlebus E, Wolska H, Blaszczyk M, et al. Subacute cutaneous lupus erythematosus versus systemic lupus erythematosus: diagnostic criteria and therapeutic implications. J Am Acad Dermatol 1998; 38: 405-12
82. Antolin J, Amerigo MJ, Cantabrana A, et al. Systemic lupus erythematosus: clinical manifestations and immunological parameters in 194 patients: subgroup classification of SLE. Clin Rheumatol 1995; 14: 678-85
83. McCurdy DK, Bick M, Gatti RA, et al. Autoantibodies in systemic lupus erythematosus. Dis Markers 1992; 10: 37-49
84. Neri R, Tavoni A, Cristofani R, et al. Antinuclear antibody profile in Italian patients with connective tissue diseases. Lupus 1992; 1: 221-7
85. Somanathan S, Suchyna TM, Siegel AJ, et al. Targeting of PCNA to sites of DNA replication in the mammalian cell nucleus. J Cell Biochem 2001; 81: 56-67
86. Sturfelt G, Bengtsson A, Klint C, et al. Novel roles of complement in systemic lupus erythematosus -hypothesis for a pathogenetic vicious circle. J Rheumatol 2000; 27: 661-3
87. Tan EM, Cohen AS, Fries JF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7
88. Yell JA, Mbuagbaw J, Burge SM. Cutaneous manifestations of systemic lupus erythematosus. Br J Dermatol 1996; 135: 355-62
89. Braverman IM. Connective tissue (rheumatic) diseases. In: Braverman IM, editor. Skin signs of systemic disease. Philadelphia: WB Saunders Company, 1981: 255-377
90. Cardinali C, Giomi B, Caproni M, et al. Maculopapular lupus rash in a young woman with systemic involvement. Lupus 2000; 9: 713-6
91. Booth SA, Moody CE, Dahl MV, et al. Dapsone suppresses integrin-mediated neutrophil adherence function. J Invest Dermatol 1992; 98: 135-40
92. Gammon WR, Briggaman RA. Bullous eruption of systemic lupus erythematosus. In: Wojnarowska F, Briggaman RA, editors. Management of blistering diseases. London: Chapman and Hall Ltd, 1990: 263-75
93. Davies MG, Marks R, Waddington E. Simultaneous systemic lupus erythematosus and dermatitis herpetiformis. Arch Dermatol 1976; 112: 1292-4
94. Miller JF, Downham TF, Chapel TA. Coexistent bullous pemphigoid and systemic lupus erythematosus. Cutis 1978; 21: 368-73
95. Blanchet PH, Auffret N, Fauchard J, et al. Association of thymoma with pemphigus foliaceous, nephrotic syndrome and lupus biology. Ann Dermatol Venereol 1981; 108: 471-2
96. Dotson AD, Raimer SS, Pursley TV, et al. Systemic lupus erythematosus occurring in a patient with epidermolysis bullosa acquisita. Arch Dermatol 1981; 117: 422-6
97. Lau M, Kaufmann-Grunzinger I, Raghunath M. A case report of a patient with features of systemic lupus erythematosus and linear IgA disease. Br J Dermatol 1991; 124: 498-502
98. Gammon WR, Briggaman RA. Bullous SLE: a phenotypically distinctive but immunologically heterogeneous bullous disorder. J Invest Dermatol 1993; 100: 28S-34S
99. Gammon WR, Woodley DT, Dole KC, et al. Evidence that anti-basement membrane zone antibodies in bullous eruption of systemic lupus erythematosus recognize epidermolysis bullosa acquisita autoantigen. J Invest Dermatol 1985; 84: 472-6
100. Woodley D, Sauder D, Talley MJ, et al. Localization of basement membrane components after dermal-epidermal junction separation. J Invest Dermatol 1983; 81: 149-53
101. Yell JA, Allen J, Wojnarowska F, et al. Bullous systemic lupus erythematosus: revised criteria for diagnosis. Br J Dermatol 1995; 132: 921-8
102. Asherson RA, Benbow A, Speirs CJ, et al. Pulmonary hypertension in hydralazine induced systemic lupus erythematosus: association with C4 null allele. Ann Rheum Dis 1986; 45: 771-3
103. Dodd HJ, Cox PM, Sarkany I. Bullous lesions in hydralazine induced lupus erythematosus -a review of three cases [abstract]. Br J Dermatol 1988; 119 Suppl. 33: 27
104. Lewis Jones MS, Evans S, Thompson CM. Erythema multiforme occurring in association with lupus erythematosus drug therapy with doxycycline. Clin Exp Dermatol 1988; 13: 245-7
105. Peterson LL. Hydrallazine-induced systemic lupus erythematosus presenting as pyoderma gangrenosum-like ulcers. J Am Acad Dermatol 1984; 10: 379-84
106. Crowson AN, Magro CM. Subacute cutaneous lupus erythematosus arising in the setting of calcium channel blocker therapy. Hum Pathol 1997; 28: 67-72
107. Buratti, Szer IS, Spencer CH, et al. Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 2001; 28: 2103-8
108. Gaubitz M, Schorat A, Schotte H, et al. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 1999; 8: 731-6
109. Dooley MA, Cosio FG, Nachman PH, et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 1999; 10: 833-9
110. Rutter A, Luger TA. Intravenous immunoglobulin: an emerging treatment for immune-mediated skin diseases. Curr Opin Investig Drugs 2002; 3: 713-9
111. Zimmerman R, Radhakrishnan J, Valeri A, et al. Advances in the treatment of lupus nephritis. Annu Rev Med 2001; 52: 63-78
112. Stanislav ML, Balabanova RM, Nikonova MF, et al. Interferon therapy effects on activation of T-lymphocytes in patients with systemic lupus erythematosus. Ter Arkh 2000; 72: 44-9
113. Duna GF, Cash JM. Treatment of refractory cutaneous lupus erythematosus. Rheum Dis Clin North Am 1995; 21: 99-115